Home
>
US Stocks
>
Bioxcel Therapeutics

Bioxcel Therapeutics (BTAI)

$19.43

+0.5

(+2.64%)▲

Market is closed - opens 7 PM, 06 Jun 2023

Insights on Bioxcel Therapeutics

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 238.0K → 206.0K (in $), with an average decrease of 13.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -123.95M → -52.79M (in $), with an average increase of 134.8% per quarter

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 31.5% return, outperforming this stock by 90.8%

Performance

  • $18.76
    $19.49
    $19.43
    downward going graph

    3.47%

    Downside

    Day's Volatility :3.77%

    Upside

    0.31%

    downward going graph
  • $8.80
    $34.13
    $19.43
    downward going graph

    54.71%

    Downside

    52 Weeks Volatility :74.22%

    Upside

    43.07%

    downward going graph

Returns

PeriodBioxcel TherapeuticsSector (Health Care)Index (Russel 2000)
3 Months
-35.53%
1.3%
-6.9%
6 Months
5.77%
-4.8%
-2.4%
1 Year
79.91%
0.7%
-6.4%
3 Years
-60.85%
26.7%
17.4%

Highlights

Market Capitalization
552.0M
Book Value
$1.82
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-6.64
Wall Street Target Price
53.0
Profit Margin
0.0%
Operating Margin TTM
-30871.43%
Return On Assets TTM
-57.32%
Return On Equity TTM
-151.47%
Revenue TTM
581.0K
Revenue Per Share TTM
0.02
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
355.0K
EBITDA
-179.0M
Diluted Eps TTM
-6.64
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.79
EPS Estimate Next Year
-5.17
EPS Estimate Current Quarter
-1.62
EPS Estimate Next Quarter
-1.6

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Bioxcel Therapeutics(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
14
Hold
3
3
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 172.77%

Current $19.43
Target $53.00

Technicals Summary

Sell

Neutral

Buy

Bioxcel Therapeutics is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bioxcel Therapeutics
Bioxcel Therapeutics
-26.21%
5.77%
79.91%
-60.85%
79.74%
Moderna, Inc.
Moderna, Inc.
-2.16%
-25.72%
-7.93%
118.1%
593.01%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.25%
0.37%
23.19%
24.21%
138.08%
Seagen, Inc.
Seagen, Inc.
-1.53%
65.54%
36.96%
29.38%
198.64%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.81%
7.25%
24.78%
26.19%
129.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bioxcel Therapeutics
Bioxcel Therapeutics
NA
NA
NA
-6.79
-1.51
-0.57
0.0
1.82
Moderna, Inc.
Moderna, Inc.
11.15
11.15
0.0
-1.77
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.0
20.0
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
25.77
25.77
0.41
13.58
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bioxcel Therapeutics
Bioxcel Therapeutics
Buy
$552.0M
79.74%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.8B
593.01%
11.15
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.2B
138.08%
20.0
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.6B
198.64%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$86.0B
129.1%
25.77
35.4%

Institutional Holdings

  • FMR Inc

    14.42%

  • Adage Capital Partners Gp LLC

    7.14%

  • State Street Corporation

    6.04%

  • BlackRock Inc

    5.02%

  • Vanguard Group Inc

    3.65%

  • Artemis Investment Management LLP

    3.37%

Corporate Announcements

  • Bioxcel Therapeutics Earnings

    Bioxcel Therapeutics’s price-to-earnings ratio stands at None

    Read More

Company Information

bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

Organization
Bioxcel Therapeutics
Employees
183
CEO
Dr. Vimal D. Mehta Ph.D.
Industry
Health Technology

Discover More

FAQs